Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) Stock Competitors & Peer Comparison
See KNSA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for KNSA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KNSA | $76.89 | +0.50% | 5.8B | 84.51 | $0.90 | N/A |
| RPRX | $57.68 | +0.73% | 25.2B | 10.81 | $5.25 | +1.60% |
| CORT | $114.25 | +5.84% | 12B | 316.49 | $0.35 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +4.17% |
| LQDA | $90.82 | +1.56% | 8B | 644.43 | $0.14 | N/A |
| TRLV | $8.81 | -2.09% | 1.5B | -20.83 | -$0.42 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| CUVL | $6.59 | -1.99% | 336.6M | N/A | N/A | N/A |
| LFMD | $3.50 | +2.84% | 172.2M | -7.12 | -$0.50 | N/A |
Stock Comparison
Royalty Pharma plc (NASDAQ: RPRX)
KNSA vs RPRX Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while RPRX trades at $57.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas RPRX's P/E ratio is 10.81. In terms of profitability, KNSA's ROE is +0.14%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, KNSA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check RPRX's competition here
Corcept Therapeutics Incorporated (NASDAQ: CORT)
KNSA vs CORT Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, CORT has a market cap of 12B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while CORT trades at $114.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas CORT's P/E ratio is 316.49. In terms of profitability, KNSA's ROE is +0.14%, compared to CORT's ROE of +0.08%. Regarding short-term risk, KNSA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CORT's competition here
Walgreens Boots Alliance, Inc. (NASDAQ: WBA)
KNSA vs WBA Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas WBA's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to WBA's ROE of -0.42%. Regarding short-term risk, KNSA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check WBA's competition here
Liquidia Corporation (NASDAQ: LQDA)
KNSA vs LQDA Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, LQDA has a market cap of 8B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while LQDA trades at $90.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas LQDA's P/E ratio is 644.43. In terms of profitability, KNSA's ROE is +0.14%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, KNSA is less volatile compared to LQDA. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LQDA's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
KNSA vs TRLV Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, TRLV has a market cap of 1.5B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while TRLV trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas TRLV's P/E ratio is -20.83. In terms of profitability, KNSA's ROE is +0.14%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, KNSA is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check TRLV's competition here
Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ: HROWL)
KNSA vs HROWL Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas HROWL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWL's ROE of -0.34%. Regarding short-term risk, KNSA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWL's competition here
Harrow Health, Inc. 11.875% Senior Notes due 2027 (NASDAQ: HROWM)
KNSA vs HROWM Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while HROWM trades at $26.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas HROWM's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to HROWM's ROE of -0.34%. Regarding short-term risk, KNSA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check HROWM's competition here
Clinuvel Pharmaceuticals Ltd. (NASDAQ: CUVL)
KNSA vs CUVL Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, CUVL has a market cap of 336.6M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while CUVL trades at $6.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas CUVL's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CUVL's ROE of N/A. Regarding short-term risk, KNSA is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CUVL's competition here
LifeMD, Inc. (NASDAQ: LFMD)
KNSA vs LFMD Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, LFMD has a market cap of 172.2M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while LFMD trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas LFMD's P/E ratio is -7.12. In terms of profitability, KNSA's ROE is +0.14%, compared to LFMD's ROE of -1.79%. Regarding short-term risk, KNSA is less volatile compared to LFMD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check LFMD's competition here
LifeMD, Inc. (NASDAQ: LFMDP)
KNSA vs LFMDP Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, LFMDP has a market cap of 160M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while LFMDP trades at $23.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas LFMDP's P/E ratio is -722.96. In terms of profitability, KNSA's ROE is +0.14%, compared to LFMDP's ROE of -1.79%. Regarding short-term risk, KNSA is more volatile compared to LFMDP. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFMDP's competition here
Circle8 Group, Inc. (NASDAQ: CIRC)
KNSA vs CIRC Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, CIRC has a market cap of 65.1M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while CIRC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas CIRC's P/E ratio is -1.64. In terms of profitability, KNSA's ROE is +0.14%, compared to CIRC's ROE of +0.00%. Regarding short-term risk, KNSA is less volatile compared to CIRC. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CIRC's competition here
Rite Aid Corporation (NYSE: RAD)
KNSA vs RAD Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas RAD's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to RAD's ROE of +2.76%. Regarding short-term risk, KNSA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check RAD's competition here
Damora Therapeutics, Inc. (NASDAQ: GLTO)
KNSA vs GLTO Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while GLTO trades at $21.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas GLTO's P/E ratio is -1.78. In terms of profitability, KNSA's ROE is +0.14%, compared to GLTO's ROE of -1.22%. Regarding short-term risk, KNSA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check GLTO's competition here
SCYNEXIS, Inc. (NASDAQ: SCYX)
KNSA vs SCYX Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, SCYX has a market cap of 33M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while SCYX trades at $5.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas SCYX's P/E ratio is -1.53. In terms of profitability, KNSA's ROE is +0.14%, compared to SCYX's ROE of -0.57%. Regarding short-term risk, KNSA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SCYX's competition here
Nasus Pharma Ltd. (AMEX: NSRX)
KNSA vs NSRX Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, NSRX has a market cap of 29.8M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while NSRX trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas NSRX's P/E ratio is -4.80. In terms of profitability, KNSA's ROE is +0.14%, compared to NSRX's ROE of +0.00%. Regarding short-term risk, KNSA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check NSRX's competition here
Stablecoin Development Corp. (AMEX: SDEV)
KNSA vs SDEV Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, SDEV has a market cap of 28.2M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while SDEV trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas SDEV's P/E ratio is -0.18. In terms of profitability, KNSA's ROE is +0.14%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, KNSA is more volatile compared to SDEV. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SDEV's competition here
Biofrontera Inc. (NASDAQ: BFRI)
KNSA vs BFRI Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, BFRI has a market cap of 16.3M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while BFRI trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas BFRI's P/E ratio is -1.19. In terms of profitability, KNSA's ROE is +0.14%, compared to BFRI's ROE of -4.77%. Regarding short-term risk, KNSA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BFRI's competition here
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD)
KNSA vs CJJD Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas CJJD's P/E ratio is -0.46. In terms of profitability, KNSA's ROE is +0.14%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, KNSA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check CJJD's competition here
SunLink Health Systems, Inc. (AMEX: SSY)
KNSA vs SSY Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas SSY's P/E ratio is -2.86. In terms of profitability, KNSA's ROE is +0.14%, compared to SSY's ROE of -0.09%. Regarding short-term risk, KNSA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SSY's competition here
POMDOCTOR Ltd (NASDAQ: POM)
KNSA vs POM Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, POM has a market cap of 5.9M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while POM trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas POM's P/E ratio is -0.17. In terms of profitability, KNSA's ROE is +0.14%, compared to POM's ROE of +0.16%. Regarding short-term risk, KNSA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POM's competition here
Paranovus Entertainment Technology Ltd. (NASDAQ: PAVS)
KNSA vs PAVS Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, PAVS has a market cap of 5.3M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while PAVS trades at $7.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas PAVS's P/E ratio is -0.07. In terms of profitability, KNSA's ROE is +0.14%, compared to PAVS's ROE of -0.27%. Regarding short-term risk, KNSA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check PAVS's competition here
Cellyan Biotechnology Co., Ltd (NASDAQ: HKPD)
KNSA vs HKPD Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, HKPD has a market cap of 4.6M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while HKPD trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas HKPD's P/E ratio is -7.01. In terms of profitability, KNSA's ROE is +0.14%, compared to HKPD's ROE of -0.14%. Regarding short-term risk, KNSA is less volatile compared to HKPD. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check HKPD's competition here
AIxCrypto Holdings, Inc. (NASDAQ: AIXC)
KNSA vs AIXC Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, AIXC has a market cap of 4.3M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while AIXC trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas AIXC's P/E ratio is -0.09. In terms of profitability, KNSA's ROE is +0.14%, compared to AIXC's ROE of -0.94%. Regarding short-term risk, KNSA is less volatile compared to AIXC. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check AIXC's competition here
MedAvail Holdings, Inc. (NASDAQ: MDVL)
KNSA vs MDVL Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas MDVL's P/E ratio is -0.05. In terms of profitability, KNSA's ROE is +0.14%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, KNSA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check MDVL's competition here
ETHZilla Corporation Warrant (NASDAQ: ATNFW)
KNSA vs ATNFW Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas ATNFW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to ATNFW's ROE of -2.41%. Regarding short-term risk, KNSA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check ATNFW's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMSP)
KNSA vs BGMSP Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMSP's ROE of -0.51%. Regarding short-term risk, KNSA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMSP's competition here
Bio Green Med Solution, Inc. (NASDAQ: BGMS)
KNSA vs BGMS Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, BGMS has a market cap of 2M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while BGMS trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas BGMS's P/E ratio is -0.26. In terms of profitability, KNSA's ROE is +0.14%, compared to BGMS's ROE of -0.51%. Regarding short-term risk, KNSA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check BGMS's competition here
AstraZeneca PLC ADRhedged (AMEX: AZNH)
KNSA vs AZNH Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas AZNH's P/E ratio is 38.35. In terms of profitability, KNSA's ROE is +0.14%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, KNSA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check AZNH's competition here
Leafly Holdings, Inc. (NASDAQ: LFLYW)
KNSA vs LFLYW Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, KNSA's ROE is +0.14%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, KNSA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check LFLYW's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFMW)
KNSA vs SBFMW Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, SBFMW has a market cap of 175.2K. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while SBFMW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas SBFMW's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to SBFMW's ROE of -0.26%. Regarding short-term risk, KNSA is less volatile compared to SBFMW. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check SBFMW's competition here
Express Scripts Holding Company (NASDAQ: ESRX)
KNSA vs ESRX Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas ESRX's P/E ratio is 10.69. In terms of profitability, KNSA's ROE is +0.14%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, KNSA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check ESRX's competition here
POZEN Inc. (NASDAQ: POZN)
KNSA vs POZN Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, POZN has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas POZN's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to POZN's ROE of +0.61%. Regarding short-term risk, KNSA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check POZN's competition here
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
KNSA vs OREX Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, OREX has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas OREX's P/E ratio is -0.14. In terms of profitability, KNSA's ROE is +0.14%, compared to OREX's ROE of -0.54%. Regarding short-term risk, KNSA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check OREX's competition here
Impax Laboratories, Inc. (NASDAQ: IPXL)
KNSA vs IPXL Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas IPXL's P/E ratio is -10.11. In terms of profitability, KNSA's ROE is +0.14%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, KNSA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for KNSA.Check IPXL's competition here
Caraco Pharmaceutical Laboratories Ltd (AMEX: CPD)
KNSA vs CPD Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, CPD has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas CPD's P/E ratio is N/A. In terms of profitability, KNSA's ROE is +0.14%, compared to CPD's ROE of N/A. Regarding short-term risk, KNSA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check CPD's competition here
Shire plc (NASDAQ: SHPG)
KNSA vs SHPG Comparison August 2026
Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KNSA stands at 5.8B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, KNSA is priced at $76.89 on the NASDAQ, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KNSA currently has a P/E ratio of 84.51, whereas SHPG's P/E ratio is 11.35. In terms of profitability, KNSA's ROE is +0.14%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, KNSA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for KNSA.Check SHPG's competition here